Wall Street fecha semana sem rumo. Grandes tecnológicas pressionam

[Xuly]

Uma questão:

Nos Softwares tipo ProRealtime e no das corretoras que usam a plataforma do SaxoBank, como é feita a alteração da cotação quando for feito o reverse split?

Ou seja, assim que acontecer o reverse split a cotação vai alterar na mesma proporção. Mas como é que os softwares lidam com isso? Senão fizerem nada fico com os gráficos todos marados.

Já agora, há alguma vantagem em entrar antes do reverse split? Ou seja, haverá algum bónus para quem já é accionista?
Pelo que li parece-me que não.


Cumps
Uly

[Shevet]

4-1??

Sim

4-1 - De 4 acções que tenhas dão-te 1

1 for 4 - aqui dizem ao troncário - dão-te 1 por cada 4 que tenhas


Quanto ao estamos #$%##" pode ser que não, o reverse é para continuar a cotar no Nasdaq o que lhe dá mais visibilidade, depois vem esse "aumento de capital" com emissão de warrants pelo meio(que sinceramente ainda não percebi bem)!!!!!!!! mas que vão capitalizar a empresa em 25 Milhões que pelo que parece será para a compra da participação de 51% na Global Medical Direct

Vamos ver..........

Abraço
Shevet

[Zezezinho]

Já esta a 0,42..................parece que vão fazer um reverse de 4-1 e depois aumento de capital!!!!!

Uiiiiiiiiiiiiiiiii isto será bom para o longo prazo, numa prespectiva de manter a visibilidade continuando a cotar no Nasdaq e capitalizar a empresa com o aumento.
No curto prazo, deve haver muita gente que não confie tanto na gestão da Generex a fugir do titulo!!!!

Ja vai com 6,131M transaccionados

4-1 ?

Approval of Reverse Stock Split

Generex management is asking its stockholders to approve a reverse stock split proposal on October 15. Management believes that a reverse stock split will put Generex in a stronger position to aggressively pursue commercialization opportunities for its buccal drug delivery and immunotherapeutic vaccine platform technologies. Based on the current price of the stock, it is anticipated that the reverse stock split ratio would not exceed 1-for-4.

If the reverse stock split is not approved, Generex's common stock will not remain listed for trading on the Nasdaq Capital Market. While the stock would then be eligible for quotation on the Over-The-Counter (OTC) Bulletin Board (OTCBB), management believes that a Nasdaq listing will afford the Company a wider variety of potentially less dilutive financing alternatives. As a development stage company, Generex must look to the capital markets to fund its on-going product development initiatives. In addition, the greater visibility and liquidity offered by a Nasdaq listing will enhance the Company's bargaining power with prospective partners and collaborators who will want comfort that Generex will have access to the capital necessary to support it contributions.

--> http://finance.yahoo.com/news/Generex-R ... l?x=0&.v=1

E mais isto:

Generex Biotechnology Corp (Nasdaq: GNBT) shares rose 25% in early market trading before falling on news the company will acquire a 51% stake in Global Medical Direct.

We're f@cked up

[Shevet]

Já esta a 0,42..................parece que vão fazer um reverse de 4-1 e depois aumento de capital!!!!!

Uiiiiiiiiiiiiiiiii isto será bom para o longo prazo, numa prespectiva de manter a visibilidade continuando a cotar no Nasdaq e capitalizar a empresa com o aumento.
No curto prazo, deve haver muita gente que não confie tanto na gestão da Generex a fugir do titulo!!!!

Ja vai com 6,131M transaccionados

[pasil74]

Veio fechar ja o GAP ou será vai descer mais um pouco

[Peftoulas]

Generex Plans Rights Offering to Stockholders Following Reverse Stock Split


WORCESTER, Mass., Oct. 11 /PRNewswire/ -- Generex Biotechnology Corporation (Nasdaq: GNBT) (www.generex.com) today announced that it plans to initiate a rights offering of common stock and warrants to its existing stockholders in the event that the stockholders approve a reverse stock split at the reconvened special meeting of stockholders scheduled for 10 a.m. EDT on Friday, October 15, 2010. The amount of the offering has not been determined, but is anticipated to permit an aggregate investment of at least $25,000,000. Certain warrant holders also will have the right to participate in the offering.

Generex is preparing to file a registration statement with the Securities and Exchange Commission forthwith following stockholder approval of a reverse stock split. Generex expects the commencement of the offering and the distribution of rights to occur promptly following effectiveness of the registration statement. Generex expects to use the proceeds from the rights offering primarily to fund its on-going research & development and product commercialization initiatives and the proposed acquisition of Global Medical Direct, LLC.

The record date for the distribution of the rights and the dates for both the subscription period and the expiration of the rights offering will be included in the final prospectus. Under the proposed terms of the rights offering, Generex would distribute one right to each holder of record of every share of its common stock that is held on the record date. Each transferable right will entitle the stockholder to purchase one unit at a subscription price to be determined prior to the effective date of the registration statement. Each unit will consist of one share of common stock and two warrants to purchase additional shares of common stock.

[Peftoulas]

Generex Reaches Agreement to Acquire 51% Stake in Global Medical Direct, a Nationwide Durable Medical Equipment and Pharmaceutical Provider Specializing in Direct-to-Consumer Diabetes Supplies


GMD's expertise in governmental & insurer reimbursement expected to be a valuable asset for Generex's diabetes platform

WORCESTER, Mass., Oct. 11 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (NasdaqCM: GNBT) (www.generex.com) today announced that it has entered into a definitive agreement to acquire a majority interest (51%) in Global Medical Direct, LLC ("GMD") of Lenexa, Kansas, a nationwide Durable Medical Equipment and Pharmaceutical provider specializing in direct-to-consumer diabetes supplies and medications (www.globalmeddirect.com).

Generex Interim President & Chief Executive Officer, Mark Fletcher stated: "The acquisition of Global Medical Direct will be a significant step toward our goal of providing a cost effective distribution platform for our over-the-counter products and our existing pipeline of diabetes prescription products as they come to market. What's more, we can now reach diabetes patients, their doctors, and insurance companies with information about the FDA Treatment IND program for Generex Oral-lyn™, which they can take advantage of right now. In a single acquisition, we are bringing together the foundations for marketing, distribution, and education components needed to make Generex Oral-lyn™, upon FDA approval, the breakthrough product we believe it to be. I have been impressed by the success and management of GMD and believe this presents an ideal strategic opportunity for Generex."

GMD provides its growing roster of over 65,000 diabetes patients with an easy-to-use, cost effective, and convenient way for them to obtain their diabetes supplies and medications through their health plans or employer and government payors such as Medicare and Medicaid. GMD provides it patients with blood glucose meters, test strips, lancets, insulin, insulin pumps, and diabetes maintenance medications and supplies. GMD manages the reimbursement process for patients, dealing directly with insurers and payors. Generex sees great value in GMD's expertise in reimbursement issues in connection with the commercialization of Generex Oral-lyn™, Metformin gum, and the other products in its pipeline.

The closing of the transaction is subject to a number of terms and conditions, including the completion of a two-year financial audit, agreement upon ancillary agreements, favorable completion of due diligence, and attainment of sufficient financing by Generex. The acquisition is anticipated to close in early January, 2011. Terms of the acquisition will be included in a Form 8-K to be filed by Generex.

Based on a continuation of revenue and net income growth rates to date, GMD's management estimates its 2010 revenue will be approximately $30 million with net income exceeding $8 million, after successful double digit growth rates over the previous five years. GMD's 2009 revenue was over $22 million. The foregoing financial information is derived from management-prepared financial statements and has not yet been audited or reviewed by independent auditors.

In addition to providing a significant, profitable revenue stream to enhance Generex's bottom line, Generex believes the acquisition of GMD will bring a number of strategic benefits to accelerate revenue growth at Generex, including:

* The means to expose patients, doctors, and insurers to the existence and benefit of the Food and Drug Administration's Treatment IND program.
* The creation of a pre-launch platform with an in-house marketing, education, and distribution environment in the event of potential full FDA approval of Generex Oral-lyn™ and new Metformin products.
* Placement of Generex's own brands of glucometers, strips, and lancets into GMD's sales and marketing engine, as well as the popular Glucose RapidSpray™ product.
* A platform for Generex's diabetes related support products including soaps, vitamins, etc.
* Direct informational engagement of patients, doctors, and insurers using GMD's educational platform and call center.
* A staff experienced in dealing with the intricacies of the reimbursement policies and paperwork for diabetes-related products across U.S. state and federal governments.
* An in-house pharmacy and dispensary that dovetails with GMD's national scale shipping and distribution facility.


Approval of Reverse Stock Split

Generex management is asking its stockholders to approve a reverse stock split proposal on October 15. Management believes that a reverse stock split will put Generex in a stronger position to aggressively pursue commercialization opportunities for its buccal drug delivery and immunotherapeutic vaccine platform technologies. Based on the current price of the stock, it is anticipated that the reverse stock split ratio would not exceed 1-for-4.

If the reverse stock split is not approved, Generex's common stock will not remain listed for trading on the Nasdaq Capital Market. While the stock would then be eligible for quotation on the Over-The-Counter (OTC) Bulletin Board (OTCBB), management believes that a Nasdaq listing will afford the Company a wider variety of potentially less dilutive financing alternatives. As a development stage company, Generex must look to the capital markets to fund its on-going product development initiatives. In addition, the greater visibility and liquidity offered by a Nasdaq listing will enhance the Company's bargaining power with prospective partners and collaborators who will want comfort that Generex will have access to the capital necessary to support it contributions.

Management recognizes that many stockholders are concerned that a reverse stock split might compromise share value. However, management is not seeking the reverse stock split in a vacuum. We believe that the strength and maturity of Generex's buccal drug delivery and immunotherapeutic vaccine pipelines, together with the synergistic benefits of the proposed GMD acquisition, and financing from the proposed rights offering to stockholders, will create a solid foundation not merely for the preservation of share value but for significant growth.

Accordingly, the Board of Directors of Generex strongly urges stockholders to vote IN FAVOR of the reverse stock split proposal on October 15.

Stockholders are asked to read the details of the reverse stock split proposal set forth in the proxy solicitation materials in respect of the special meeting issued August 23, 2010 and accessible on our website at http://investor.generex.com/sec.cfm.

Should stockholders have any questions regarding the proxy voting procedures (including changing previously cast votes), please contact Legend Securities, Inc. by telephone at 877-317-7526 or via email at gnbtproxy@legendsecurities.com for US residents. Non-US residents should contact Generex directly at 800-391-6755 or contact their broker/dealer.

More on GMD:

GMD utilizes its 125+ person highly-trained, well-educated staff and call center, to maintain the ideal personal one-to-one customer relationship management environment with diabetes sufferers across the United States. Its staff establishes a continuing and ongoing dialogue with consumers to help maintain their compliance with blood glucose testing and provides them with glucometers, blood glucose test strips, lancets, insulin, and related products. GMD management expects that it will continue to recruit more than 2,500 new patients on a monthly basis. GMD is able to compile information on patient use of lancets and testing strips, thus providing a baseline for the monitoring of glucose management compliance. Glucose management compliance is of great interest to the patients' doctors and insurers and provides a reason for both groups to enroll their patients under GMD's service umbrella. Compliance in the diabetes world is essential to minimize glycemic attacks and future complications

Generex sees great value in GMD's existing diabetes educational platform. There are over 50 million pre-diabetics in the United States alone and this education strategy will allow Generex to continue to introduce and present Generex Oral-lyn™ (upon FDA approval) as well as Generex's other products to GMD's entire roster of patients as well as future consumers. Additionally, Generex, through its website and latest branding initiatives in the social media world (on Twitter, Facebook, LinkedIn, etc.), will help to serve as a platform for GMD, bringing further exposure and patient recruitment opportunities to increase its customer base.

GMD's in-house pharmacy permits the company to seamlessly handle both prescription and non-prescription drugs and handle the state-by-state intricacies of paperwork necessary for reimbursement. Generex also sees exceptional value in GMD's streamlined, and expandable packaging and shipping facility, which ships thousands of packages each month to a growing number of diabetes patients all across the United States. In anticipation of eventual marketing of Generex Oral-lyn™ when FDA approval is received, GMD's facility represents the ideal, centrally located, fully equipped national warehousing and shipping depot.

Upon completion of the acquisition, Generex intends to work closely with GMD's current management team, including Joseph Corso, Robert Shea, and Mark Franz who will remain in place to continue GMD's expansion. Joe Moscato and his team at Seahawk Capital Partners, Inc. are providing advisory services on behalf of Generex in connection with the acquisition.

Robert Shea, President & Chief Executive Officer of Global Medical Direct stated: "We are excited at the prospect of teaming up with Generex. The Generex team brings tremendous industry knowledge, expertise, and innovative technologies which will enable us to expand our market opportunities and drive both top and bottom line growth to new levels. The benefits of this combination will be immediately felt by our diabetes patients, providing them access to several new Generex OTC products, but, more importantly, they will have access to the new Generex Oral-Lyn™ buccal insulin spray product under the FDA Treatment IND program. The Generex pipeline of pharmaceutical products expected to be introduced over the next 3-5 years will position Global Medical Direct as the industry leader in the direct-to-consumer diabetes mail order segment."

Comentarios?!!

[pedro200]

07:06 AM Eastern Daylight Time, 10/11/2010 (MidnightTrader) -- The company announced Friday night it will make a key material announcement before the market open today.

Price: 0.575, Change: +0.145, Percent Change: +33.7
(
C) 2010 MidnightTrader, Inc. All rights reserved.

è certo que ainda são poucas as acções negociadas mas esta quase no 0,60usd

A noticia completa com os links para os webcast das conferencias de 12 e 19 de Outubro

Generex to Release Material Announcement on October 11, 2010

WORCESTER, Mass., Oct. 8 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT) (www.generex.com) announced today that it plans to make a key material announcement on Monday, October 11th, 2010 before market open.

In addition to Monday's announcement, Generex senior management will address analysts' and shareholders' questions directly in two open conferences:

Tuesday, October 12, 2010, Generex will hold a conference call and webcast:

Date: October, 12, 2010

Time 10:00 am EDT

Toll-Free Dial-In Number: +1 877 / 303-7204

International Dial-In Number: +1 224 / 357-2384

Webcast: http://investor.generex.com/events.cfm

Tuesday, October 19, 2010, Generex will hold a live video webcast from the NASDAQ Marketsite:

Date: October, 19, 2010

Time: 1:00 pm EDT

Where: NASDAQ Marketsite, Times Square, 43rd & Broadway, NYC

•To attend in-person, RSVP absolutely required for building security. Please contact bradley.smith@muncmedia.com


Webcast: http://investor.generex.com/events.cfm

Parece que não esta a negociar!!!???? Mas o que é que iam anunciar antes da abertura dos mercados??? E porque é que esteve a negociar até agora???? Alguem sabe??

Abraço
Shevet

Já não seria a primeira vez que a gnbt divulga notícias a meio da sessão!

[Shevet]

07:06 AM Eastern Daylight Time, 10/11/2010 (MidnightTrader) -- The company announced Friday night it will make a key material announcement before the market open today.

Price: 0.575, Change: +0.145, Percent Change: +33.7
(
C) 2010 MidnightTrader, Inc. All rights reserved.

è certo que ainda são poucas as acções negociadas mas esta quase no 0,60usd

A noticia completa com os links para os webcast das conferencias de 12 e 19 de Outubro

Generex to Release Material Announcement on October 11, 2010

WORCESTER, Mass., Oct. 8 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT) (www.generex.com) announced today that it plans to make a key material announcement on Monday, October 11th, 2010 before market open.

In addition to Monday's announcement, Generex senior management will address analysts' and shareholders' questions directly in two open conferences:

Tuesday, October 12, 2010, Generex will hold a conference call and webcast:

Date: October, 12, 2010

Time 10:00 am EDT

Toll-Free Dial-In Number: +1 877 / 303-7204

International Dial-In Number: +1 224 / 357-2384

Webcast: http://investor.generex.com/events.cfm

Tuesday, October 19, 2010, Generex will hold a live video webcast from the NASDAQ Marketsite:

Date: October, 19, 2010

Time: 1:00 pm EDT

Where: NASDAQ Marketsite, Times Square, 43rd & Broadway, NYC

•To attend in-person, RSVP absolutely required for building security. Please contact bradley.smith@muncmedia.com


Webcast: http://investor.generex.com/events.cfm

Parece que não esta a negociar!!!???? Mas o que é que iam anunciar antes da abertura dos mercados??? E porque é que esteve a negociar até agora???? Alguem sabe??

Abraço
Shevet

[Ricardostc]

Dependendo do que está para sair , após a reabertura o titulo poderá dar um saltinho até os 0.63.

[pedro200]

Pararam a negociação do titulo !??

Parece que sim!

[Ricardostc]

Pararam a negociação do titulo !??

[pvg80713]

mesmo a money.cnn.com
se escolheres a GNBT, te mostra a premarket.
cmps
pvg

[pedrojcc]

Marketwatch ou CNBC, GNBT agora está a cotar a 0.51 por exemplo.espero ter ajudado

[Xuly]

Viva,
Onde vais ver essas cotações antes da abertura mercados?

Edit:
Já descobri...
O google faz milagres.

Já agora, alguém costuma negociar em pre-trade?

Thanks
Uly

[pasil74]

07:06 AM Eastern Daylight Time, 10/11/2010 (MidnightTrader) -- The company announced Friday night it will make a key material announcement before the market open today.

Price: 0.575, Change: +0.145, Percent Change: +33.7
(
C) 2010 MidnightTrader, Inc. All rights reserved.

è certo que ainda são poucas as acções negociadas mas esta quase no 0,60usd

[pedro200]

great artikel:

http://biomedreports.com/generex-issues-letter-to-shareholders.html

Sim, muito bom artigo! Essa informação foi divulgada na passada terça-feira. O novo CEO parece querer ganhar a confiança dos investidores, através de uma melhor comunicação com o mercado.

Nessa carta aos accionistas ficamos a saber muita coisa que até ao momento não era conhecida! Foi actualizado o número de pacientes na fase III do Oral-Lyn e ficamos a saber o que se passa de concreto na índia!

Neste momento na Índia está a decorrer a fase IV do Oral-Lyn! Esta informação já era do conhecimento público. A novidade está no número de pacientes que está a ser analisado para obter aprovação por parte da agência Indiana do medicamento (não sei se esta designação está correcta). Gostava era de saber para quando está prevista a conclusão do estudo.

Outro facto a ter em atenção, é que o estudo da fase II do AE37 deve estar a terminar. Basta ver a seguinte informação de Dezembro de 2009 e fazer as contas:

Generex Presents Encouraging Interim Results of Phase II Breast Cancer Study
[b]December 14, 2009
[/b]
Novel Immunotherapeutic Breast Cancer Vaccine on Track for Demonstration of Efficacy

WORCESTER, Mass., Dec 14, 2009 (GlobeNewswire via COMTEX News Network) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) today announced presentation of interim results from a Phase II efficacy study of a novel immunotherapeutic vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). The results were presented at the 32nd Annual San Antonio Breast Cancer Symposium (www.sabcs.org). The trial is being conducted by COL George Peoples, MD, a collaborator of Antigen Express working at the Brooke Army Medical Center.

The presentation, entitled Interim analysis of a randomized phase II study of the novel Ii-Key hybrid HER2/neu peptide (AE37) vaccine to prevent breast cancer recurrence: United States Military Cancer Institute Clinical Trials Group Study I-05, showed that only half the number of patients in the treatment arm of the study relapsed compared to those not receiving the vaccine. The trial is a fully randomized and controlled study examining the rate of relapse in patients diagnosed with node-positive or high risk node negative breast cancer. The final endpoint will examine the relapse rate after two years; the results presented at the conference were those observed in patients 13.5 months after treatment.

Antigen Express, Generex's immunotherapy division, is developing novel synthetic peptide vaccines for potent and specific stimulation of CD4+ T helper cells. The vaccine being studied in this trial, AE37, was shown to be safe, well-tolerated and produced the desired immunological activity in both a Phase I trial in breast cancer patients and a Phase I trial in patients with prostate cancer. AE37 is also the subject of an additional Phase I clinical trial in patients with breast or ovarian cancer in which it is being combined with another immunotherapeutic peptide.

In addition to cancer, the proprietary Antigen Express technology is being applied to vaccine development for infectious diseases. In particular, a synthetic peptide vaccine is currently being developed for the H1N1 swine flu virus.

[nk667]

great artikel:

http://biomedreports.com/generex-issues-letter-to-shareholders.html

[pedro200]

http://www.sabcs.org/ProgramSchedule/PosterSessions.asp?SessionGroupID=79

The title of the unexpected abstract at this year's SABCS Annual Meeting is Combination Immunotherapy for Breast Cancer Patients: Safety and Immunologic Data from a Phase II Trial Administering a HER2/neu-Derived Peptide vaccine (AE37+GM-CSF) Sequentially or Concurrently with Trastuzumab in the Adjuvant Setting.

"Trastuzumab = Herceptin"
in http://pipelinereview.blogspot.com/
Agora comparem com esta notícia:

AE37's Market Potential

Roche and Genentech's (DNA) blockbuster drug, Herceptin, which also zeroes in on cancer that is over-expressing HER-2/neu, can be used only in patients expressing the highest level of HER-2, or about 25 percent of breast cancer patients. In comparison, the AE37 peptide vaccine stimulates the immune system to recognize tumor cells in patients with a lower expression of HER-2, so that 75 percent of breast cancer patients would respond to Antigen's vaccine. Herceptin sales in 2008 were $1.8 billion, and reached approximately $2.5 billion in the first half of 2009.

The potential market for Antigen's vaccine could be even larger since it can be used in more HER-2 patients, and when considering the licensing potential of using AE37 in combination with treatments from other firms. Antigen Express has stated it believes there could be a synergistic response if they use Herceptin with an immunological drug like AE37, but currently the company is more focused on looking at AE37 alone or in combination with other peptides (such as in the AE37 Combo Vaccine).

http://seekingalpha.com/article/198633- ... urce=yahoo

AC:

estás a ver o filme? (caso os resultados sejam positivos)

Bom fim de semana

[pedro200]

After Hours Last:
$ .51
After Hours High: $ .56 After Hours Volume: 100,300

Máximo: 0,56 (After Hours)
Volume: 100300 - Não é normal

Pedro,

Como te venho dizendo á uns tempos atrás , esta é a minha única penny stock que tenho nas carteiras, o potencial é tão grande, que vale a pena o risco que possamos vir a ter. No entanto para quem não está habituado a estas andanças, não recomendo entrar em penny stocks, mas a GNBT pode vir a ser a galinha dos ovos de OURO. Que fecho estranho no after-hours, e transacionou mais de 100 mil titulos, algo anormal. Segunda-feira temos festa.... Haver vamos...

Sim, Muito Estranho!

Um abraço!

[AC Investor Blog]

After Hours Last:
$ .51
After Hours High: $ .56 After Hours Volume: 100,300

Máximo: 0,56 (After Hours)
Volume: 100300 - Não é normal

Pedro,

Como te venho dizendo á uns tempos atrás , esta é a minha única penny stock que tenho nas carteiras, o potencial é tão grande, que vale a pena o risco que possamos vir a ter. No entanto para quem não está habituado a estas andanças, não recomendo entrar em penny stocks, mas a GNBT pode vir a ser a galinha dos ovos de OURO. Que fecho estranho no after-hours, e transacionou mais de 100 mil titulos, algo anormal. Segunda-feira temos festa.... Haver vamos...

[pedro200]

http://www.sabcs.org/ProgramSchedule/Po ... GroupID=79

The title of the unexpected abstract at this year's SABCS Annual Meeting is Combination Immunotherapy for Breast Cancer Patients: Safety and Immunologic Data from a Phase II Trial Administering a HER2/neu-Derived Peptide vaccine (AE37+GM-CSF) Sequentially or Concurrently with Trastuzumab in the Adjuvant Setting.

"Trastuzumab = Herceptin"
in http://pipelinereview.blogspot.com/
Agora comparem com esta notícia:

AE37's Market Potential

Roche and Genentech's (DNA) blockbuster drug, Herceptin, which also zeroes in on cancer that is over-expressing HER-2/neu, can be used only in patients expressing the highest level of HER-2, or about 25 percent of breast cancer patients. In comparison, the AE37 peptide vaccine stimulates the immune system to recognize tumor cells in patients with a lower expression of HER-2, so that 75 percent of breast cancer patients would respond to Antigen's vaccine. Herceptin sales in 2008 were $1.8 billion, and reached approximately $2.5 billion in the first half of 2009.

The potential market for Antigen's vaccine could be even larger since it can be used in more HER-2 patients, and when considering the licensing potential of using AE37 in combination with treatments from other firms. Antigen Express has stated it believes there could be a synergistic response if they use Herceptin with an immunological drug like AE37, but currently the company is more focused on looking at AE37 alone or in combination with other peptides (such as in the AE37 Combo Vaccine).

http://seekingalpha.com/article/198633- ... urce=yahoo

[pedro200]

After Hours Last:
$ .51
After Hours High: $ .56 After Hours Volume: 100,300

Máximo: 0,56 (After Hours)
Volume: 100300 - Não é normal

[pedro200]

:)

A próxima semana vai ser agitada!

AE37! Oral-Lyn!

http://finance.yahoo.com/news/Generex-t ... l?x=0&.v=1

Tuesday, October 12, 2010, Generex will hold a conference call and webcast:

Date: October, 12, 2010

Time 10:00 am EDT

Toll-Free Dial-In Number: +1 877 / 303-7204

International Dial-In Number: +1 224 / 357-2384

Webcast: http://investor.generex.com/events.cfm

Tuesday, October 19, 2010, Generex will hold a live video webcast from the NASDAQ Marketsite:

Date: October, 19, 2010

Time: 1:00 pm EDT

Where: NASDAQ Marketsite, Times Square, 43rd & Broadway, NYC

[nk667]

11-Oct-10 Earnings announcement

http://finance.yahoo.com/q/ce?s=GNBT+Company+Events